CI 10-Q Quarterly Reports

The Cigna Group reported a significant increase in net income for the nine months ended September 30, 2025, driven by the absence of a substantial prior-year investment impairment. Total revenues grew by 12% year-over-year, largely due to strong performance in Pharmacy revenues, which increased by 17%. This growth was primarily fueled by higher utilization and customer expansion within the Evernorth Health Services segment. However, the Cigna Healthcare segment experienced a revenue decline of 9%, largely attributable to the divestiture of its Medicare Advantage business. Despite this, the company managed its expenses effectively, with Selling, General, and Administrative (SG&A) expenses remaining relatively flat year-over-year when excluding the impact of strategic optimization programs. The company also strengthened its balance sheet by issuing new senior notes and repaying existing debt, demonstrating a proactive approach to capital management.

The Cigna Group reported solid financial results for the six months ended June 30, 2025, demonstrating resilience and strategic execution. Total revenues increased by 13% year-over-year, reaching $132.68 billion, primarily driven by a significant 17% surge in Pharmacy revenues, fueled by customer growth in Evernorth Health Services. This strong top-line performance, coupled with disciplined cost management, resulted in a substantial 125% increase in Shareholders' Net Income to $2.86 billion, largely benefiting from the absence of a significant prior-year equity impairment. The company also successfully completed the divestiture of its Medicare Advantage and related businesses to HCSC, strengthening its strategic focus and financial position. Operationally, the company continues to execute its growth strategies across its Evernorth Health Services segment, which saw a 16% increase in adjusted revenues. While the Cigna Healthcare segment experienced an 18% decrease in adjusted revenues for the quarter due to the HCSC transaction, the underlying U.S. Healthcare businesses showed premium growth. The company maintained a strong liquidity position with significant undrawn committed capacity and a robust cash flow from operations, enabling continued capital deployment through dividends and share repurchases. Management remains confident in the company's ability to navigate market dynamics and deliver long-term shareholder value.

Cigna Group (CI) reported a significant turnaround in its financial performance for the first quarter of 2025, moving from a net loss of $277 million in Q1 2024 to a net income of $1.323 billion, resulting in a diluted EPS of $4.85 compared to ($0.97) in the prior year. This improvement was largely driven by the absence of substantial net investment losses experienced in Q1 2024, which were primarily related to equity security impairments. Total revenues saw a robust 14% increase year-over-year, reaching $65.5 billion, fueled by growth across all segments, particularly a 16% rise in Pharmacy revenues. The company also successfully completed the divestiture of its Medicare Advantage and related businesses to HCSC for an increased purchase price, which is expected to provide additional proceeds in Q4 2025. While operating expenses rose 16%, the strong revenue growth and the elimination of prior-year investment losses contributed to the substantial net income improvement. Cigna also announced a new $6.5 billion credit facility in April 2025, underscoring its strong liquidity position.

The Cigna Group (CI) reported total revenues of $63.7 billion for the third quarter of 2024, a significant increase of 30% year-over-year, driven by robust growth in its Evernorth Health Services segment. Shareholders' net income for the quarter was $739 million, or $2.63 per diluted share, a decrease of 48% compared to the prior year, primarily due to a substantial impairment loss on equity securities related to its investment in VillageMD. Despite the decline in net income, adjusted income from operations, a non-GAAP measure that excludes special items like investment losses, increased by 5% to $2.1 billion, signaling underlying operational strength. The company's medical customer base saw a slight decrease of 3%, primarily impacting the Individual and Family Plans within the U.S. Healthcare segment. However, Evernorth's Pharmacy Benefit Services and Specialty and Care Services segments demonstrated strong revenue growth, supported by increased prescription drug utilization and customer expansion. The company is also advancing its strategic divestiture of its Medicare Advantage business, expected to close in the first quarter of 2025.

Cigna Group's Q2 2024 report indicates a strong increase in total revenues, driven primarily by a significant rise in pharmacy revenues, reflecting growth from new clients and organic expansion within its Evernorth Health Services segment. While total shareholders' net income saw a decrease year-over-year, largely due to a substantial impairment of equity securities in Q1 2024, the adjusted income from operations showed a healthy increase, demonstrating resilience in underlying business performance. The company's Cigna Healthcare segment experienced moderate revenue growth and improved profitability, supported by higher premium rates and expense management, though a slight decline in medical customers was noted. Liquidity remains robust with significant cash reserves and undrawn credit facilities. The company continues to execute on its capital deployment strategy, including substantial share repurchases and the upcoming sale of its Medicare Advantage businesses, which is expected to yield approximately $3.7 billion. Overall, Cigna appears to be navigating a dynamic healthcare landscape effectively, with core business segments showing operational strength despite market headwinds and one-time financial impacts.

Cigna Group (CI) reported a net loss of $277 million, or -$0.97 per diluted share, for the first quarter of 2024, a significant decline from a net income of $1.3 billion, or $4.24 per diluted share, in the same period last year. This net loss was primarily driven by a substantial $1.8 billion net realized investment loss, largely due to an impairment of equity securities, specifically its investment in VillageMD. Despite the GAAP net loss, the company's adjusted income from operations, a non-GAAP measure, increased by 16% to $1.875 billion, or $6.47 per diluted share, reflecting the underlying operational strength of its Evernorth Health Services and Cigna Healthcare segments. Total revenues saw a significant increase of 23% to $57.3 billion, driven by a 31% surge in pharmacy revenues, largely attributed to the onboarding of Centene. The Cigna Healthcare segment's adjusted revenues grew 4%, supported by higher premium rates. The company also announced its agreement to sell its Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation (HCSC) for approximately $3.3 billion, expected to close in Q1 2025. This strategic divestiture, coupled with robust operational performance in its core segments, positions Cigna for future focus and potential capital deployment.

Cigna Group's (CI) third quarter 2023 results show a year-over-year decrease in Shareholders' Net Income, largely due to the absence of a significant gain from asset divestitures in the prior year. However, on an adjusted basis, the company demonstrated resilience, with Adjusted Income from Operations showing an increase for the quarter, driven by solid performance in its Evernorth Health Services and Cigna Healthcare segments. Total revenues saw a healthy increase, propelled by growth in Pharmacy revenues and Premiums, alongside a notable rise in Fees and other revenues, indicating strong top-line expansion. Operational highlights include a significant increase in medical customers, reflecting successful growth strategies. The company's liquidity remains robust, supported by substantial cash and investment reserves, and available credit facilities. While facing headwinds from increased medical costs and selling, general, and administrative expenses, Cigna Group's strategic investments in technology and care solutions appear to be laying the groundwork for future growth. Investors should monitor the ongoing litigation and regulatory matters, particularly the Medicare Advantage risk adjustment investigations, which, despite recent settlements, carry inherent uncertainties.

The Cigna Group reported solid top-line growth for the second quarter of 2023, with total revenues increasing by 7% to $48.6 billion, driven by strong performance in both Evernorth Health Services and Cigna Healthcare segments. While the company experienced a slight decrease in shareholders' net income to $1.46 billion from $1.56 billion in the prior year's quarter, this was largely due to lower adjusted income from operations and the absence of earnings from divested businesses. Evernorth Health Services demonstrated robust growth in adjusted revenues, up 10%, fueled by specialty pharmacy and increased client services. Cigna Healthcare also saw a 12% increase in adjusted revenues, supported by customer growth and higher premium rates. The company's capital position remains strong, with significant liquidity and a stable debt-to-capitalization ratio. Strategic investments in healthcare services, including a notable investment in VillageMD, signal continued focus on expanding care delivery capabilities and long-term growth.

The Cigna Group reported a solid first quarter in 2023, demonstrating revenue growth and consistent operational performance. Total revenues increased by 6% year-over-year to $46.5 billion, driven by strong contributions from both the Evernorth Health Services and Cigna Healthcare segments. Pharmacy revenues saw a 5% increase, while premiums rose by 6%, reflecting growth in customer base and strategic pricing adjustments. Despite a slight dip in net investment income, the company maintained profitability, with shareholders' net income growing by 6% to $1.27 billion. The company's operational efficiency was evident, though selling, general, and administrative expenses saw an increase due to strategic investments aimed at future growth. Importantly, Cigna Healthcare experienced a significant 10% increase in medical customers, highlighting its expanding market reach. The company also continued its capital return strategy, with share repurchases and dividend payments, while managing its debt levels effectively, maintaining a debt-to-capitalization ratio of 42.2%.

Cigna Group (CI) reported solid financial results for the nine months ended September 30, 2022. Total revenues increased by 5% to $134.765 billion. Shareholders' net income saw a significant increase of 29% to $5.499 billion, driven largely by a substantial gain on the sale of international businesses and improved adjusted income from operations. The company demonstrated strong operational performance, with adjusted income from operations rising by 7% to $5.770 billion. This growth was supported by expansion in its Evernorth segment and improved medical cost ratios in the Cigna Healthcare segment. The sale of international businesses provided a significant boost to net income, while the company continued its capital return strategy through share repurchases and dividends.

Cigna Group (CI) reported strong financial results for the second quarter and first half of 2022, demonstrating robust revenue and profit growth across its key segments. Total revenues increased by 5% and 6% for the three and six months ended June 30, 2022, respectively, driven by growth in both its Evernorth and Cigna Healthcare segments. Shareholders' net income saw a notable increase of 7% for the quarter and 5% for the first half, reflecting improved operational performance and the absence of certain one-time charges seen in the prior year. Adjusted income from operations, a key non-GAAP metric, showed even stronger growth, rising 10% for the quarter and 13% for the first half, underscoring the company's underlying business strength. The company also highlighted significant strategic developments, including the completion of the sale of its international life, accident, and supplemental benefits businesses for approximately $5.4 billion, which is expected to be utilized primarily for share repurchases. Furthermore, Cigna announced a new five-year agreement with Kaiser Permanente to provide access to its PPO provider network and specialty pharmacy services, indicating strategic expansion and partnership opportunities. The company continues to manage its capital effectively, repurchasing shares and maintaining a strong liquidity position.

Cigna Group's (CI) first quarter 2022 filing showcases solid revenue growth and improved profitability, driven by strong performance in its Evernorth and Cigna Healthcare segments. Total revenues increased by 7% year-over-year to $44.0 billion, with adjusted revenues up 8% to $44.1 billion, reflecting growth in pharmacy, premiums, and fees. Net income attributable to shareholders rose slightly to $1.183 billion, or $3.68 per diluted share, compared to $1.161 billion, or $3.30 per diluted share, in the prior year's quarter. The company's adjusted income from operations saw a significant increase of 16% to $1.931 billion, with diluted EPS on this basis growing by 27% to $6.01, underscoring operational improvements and effective cost management. Operationally, Cigna Healthcare experienced a 3% increase in adjusted revenues, boosted by specialty contributions and higher premium rates, alongside a notable 23% rise in pre-tax adjusted income from operations. The Evernorth segment also demonstrated strength with a 10% increase in adjusted revenues, driven by specialty claims volume and price increases, leading to a 6% growth in pre-tax adjusted income from operations. The company is progressing with its strategic divestiture of international life, accident, and supplemental benefits businesses, expected to close in the second quarter of 2022, and continues to focus on operational efficiency and capital return to shareholders through dividends and share repurchases.

Cigna Group (CI) reported solid revenue growth for the nine months ending September 30, 2021, with total revenues increasing by 8% year-over-year to $128.4 billion. This growth was primarily driven by a strong performance in the Evernorth segment, which saw a 13% increase in adjusted revenues, and continued growth in U.S. Medical premiums. Despite overall revenue growth, shareholders' net income saw a slight decrease of 2% for the nine-month period, mainly due to a decline in adjusted income from operations, impacted by unfavorable COVID-19 related costs and the absence of earnings from the divested Group Disability and Life business. However, diluted earnings per share saw a 6% increase due to a favorable effect of share repurchases. The company continues to strategically manage its portfolio, evidenced by the announced sale of its international life, accident, and supplemental benefits businesses for $5.75 billion and the acquisition of MDLIVE for $2.0 billion, which will bolster its virtual care offerings. Cigna's balance sheet remains robust, with total assets of $154.3 billion and shareholders' equity of $47.4 billion. The company is actively returning capital to shareholders through dividends and share repurchases, underscoring its commitment to shareholder value. Investors should monitor the ongoing integration of MDLIVE and the successful execution of the international divestiture, as well as the continued impact of COVID-19 on medical costs and utilization.

Cigna Group (CI) reported a solid performance for the quarter ended June 30, 2021, with total revenues increasing by 10% year-over-year to $43.1 billion. This growth was primarily driven by a 13% increase in pharmacy revenues, largely attributable to the Evernorth segment, which saw strong business and customer growth. Despite an increase in medical costs and other benefit expenses due to the resumption of medical care and COVID-19 related costs, the company managed to control selling, general, and administrative expenses, which decreased by 12%. Shareholders' net income for the quarter was $1.47 billion, a decrease from the prior year, impacted by higher COVID-19 related costs and the absence of certain favorable tax benefits. For the six-month period, total revenues grew 8% to $84.1 billion. While shareholders' net income decreased by 10%, the company's adjusted income from operations saw a more moderate decline of 11%, highlighting the impact of one-time items and the sale of the Group Disability and Life business. The company completed the acquisition of MDLIVE, a virtual care platform, to further enhance its Evernorth segment's offerings. Cigna continued to prioritize capital return to shareholders through share repurchases and dividends, demonstrating a commitment to shareholder value while navigating a dynamic healthcare landscape.

Cigna Group (CI) reported revenues of $40.97 billion for the first quarter of 2021, an increase of 7% compared to the same period in 2020. Shareholders' net income saw a slight decrease of 2% to $1.16 billion, or $3.30 per diluted share, primarily impacted by lower adjusted income from operations and the absence of certain tax benefits from the prior year. The company's Evernorth segment continued its strong performance, with revenues growing 13%, driven by pharmacy and health services. However, the U.S. Medical segment experienced an 18% decrease in pre-tax adjusted income from operations, largely due to unfavorable COVID-19 related impacts and the sale of the Group Disability and Life business. The company also repurchased $2.8 billion of its stock during the quarter and completed the acquisition of virtual care platform MDLIVE. Financially, Cigna demonstrated robust revenue growth, particularly within its Evernorth segment, highlighting the success of its diversified health services strategy. While overall net income saw a modest dip, this was largely attributable to temporary factors and strategic business adjustments. The company's active share repurchase program signals confidence in its financial position and commitment to returning capital to shareholders. Investors should note the ongoing impact of COVID-19 on the U.S. Medical segment, while recognizing the resilience and growth of the Evernorth business, which remains a key driver of future performance. The company also strengthened its liquidity position through new revolving credit agreements.

Cigna Group (CI) reported its third quarter 2020 financial results, showing continued revenue growth driven by its Evernorth segment and U.S. Medical premiums. Total revenues increased by 6% year-over-year to $40.96 billion for the three months ended September 30, 2020. Shareholders' net income saw a modest increase of 3% to $1.39 billion, or $3.78 per diluted share. The company's performance was influenced by the ongoing COVID-19 pandemic, which led to a deferral of care earlier in the year, followed by a return to more typical utilization levels in the third quarter. While this resulted in some increased medical costs and elevated life insurance claims, it also contributed to higher earnings in the U.S. Medical segment due to lower-than-expected utilization earlier in the period. Cigna also continues to progress with strategic initiatives, including the expected sale of its U.S. Group Disability and Life insurance business.

Cigna Group reported solid financial results for the second quarter and first half of 2020, demonstrating resilience amidst the COVID-19 pandemic. Total revenues saw a modest increase, driven by growth in Pharmacy and Premiums, though partially offset by a decline in Fees and Other Revenues. Net income and Shareholders' net income showed significant year-over-year improvements, largely attributable to strong performance in the Integrated Medical and Health Services segments. This improvement was fueled by decreased medical utilization due to deferred care, which more than offset increased COVID-19 related costs and premium relief programs. The company also made strategic moves, including progressing the sale of its U.S. Group Disability and Life insurance business and actively managing its capital structure through debt repayment and share repurchases. Cigna highlighted its proactive approach to supporting customers, providers, and communities during the pandemic, underscoring its commitment to affordability, simplicity, and predictability in healthcare delivery. The company maintained a strong liquidity position, with substantial cash and committed credit facilities available.

Cigna Group's (CI) Q1 2020 filing shows a slight increase in total revenues to $38.5 billion, up from $37.9 billion in the prior year's quarter. However, shareholders' net income saw a decline of 14% to $1.18 billion, translating to diluted earnings per share of $3.15, down from $3.56. This decrease was attributed to the absence of earnings from transitioning clients in 2019, costs related to a debt tender and redemption, and realized investment losses. Despite these challenges, the company reported growth in adjusted income from operations, up 17% to $1.76 billion, driven by strength in its Health Services and Integrated Medical segments. The company also provided an update on its response to the COVID-19 pandemic, highlighting initiatives to ensure affordability and access to care, support healthcare providers, and care for its workforce. The immediate financial impact of COVID-19 on the company's Q1 results was deemed immaterial, though future impacts remain uncertain. Cigna continued its strategic focus on divesting non-core assets, with the sale of its U.S. Group Disability and Life insurance business progressing towards an expected close in Q3 2020.

Cigna Group's (CI) third-quarter 2019 results show significant year-over-year growth, largely driven by the full integration of Express Scripts, acquired in late 2018. Total revenues more than tripled compared to the prior year period, reflecting substantial contributions from the Health Services segment, which encompasses Express Scripts' pharmacy benefit management and medical management services. Net income and earnings per share also saw robust increases, though the growth rate for EPS was tempered by dilution from shares issued in connection with the Express Scripts acquisition. The company demonstrated operational improvements across key segments, notably in Integrated Medical, and managed its expenses effectively despite the scale of the integration. Cigna's strengthened financial position and diverse business segments provide a solid foundation for future performance, although investors should remain aware of ongoing integration costs and potential regulatory headwinds within the healthcare industry.

Cigna Group (CI) reported strong financial results for the second quarter and first half of 2019, largely driven by the significant contribution from the acquisition of Express Scripts. Total revenues surged by 235-238% year-over-year for the respective periods, reaching $38.8 billion for the quarter and $76.8 billion for the six months. This growth is primarily attributable to the inclusion of Express Scripts' pharmacy benefit management and medical management businesses. Shareholders' net income saw a substantial increase of 75% for the quarter and 61% for the six months, reaching $1.41 billion and $2.78 billion, respectively. This growth, while impressive, was somewhat tempered by the dilution from shares issued in connection with the Express Scripts acquisition, leading to a more moderate increase in diluted earnings per share. The company's focus on integrating Express Scripts and optimizing its health services and integrated medical segments positions it for continued operational efficiency and market competitiveness.

Cigna Group (CI) reported strong first-quarter 2019 results, significantly driven by the recent acquisition of Express Scripts. Total revenues surged by 232% year-over-year to $37.9 billion, primarily due to the inclusion of Express Scripts' pharmacy and medical management businesses. Shareholders' net income grew 50% to $1.37 billion, or $3.56 per diluted share. Adjusted income from operations, a key non-GAAP metric, also increased by 48% to $1.5 billion, though diluted EPS on this basis saw a slight decrease to $3.90 due to share dilution from the acquisition. The Health Services segment, largely comprising the Express Scripts business, showed substantial revenue growth. The Integrated Medical segment also demonstrated resilience with a 13% increase in adjusted revenues and improved profitability. Despite a significant increase in interest expense related to acquisition financing, the company's overall financial performance reflects a successful integration of Express Scripts, positioning Cigna for continued growth in the health services landscape.